Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Br J Haematol. 2021 Mar;192(6):1092-1096. doi: 10.1111/bjh.16724. Epub 2020 May 28.
Diagnosis of pyruvate kinase deficiency (PKD), the most common cause of hereditary non-spherocytic haemolytic anaemia, remains challenging in routine practice and no biomarkers for clinical severity have been characterised. This prospective study enrolled 41 patients with molecularly confirmed PKD from nine North American centres to evaluate the diagnostic sensitivity of pyruvate kinase (PK) enzyme activity and PK:hexokinase (HK) enzyme activity ratio, and evaluate the erythrocyte PK (PK-R) protein level and erythrocyte metabolites as biomarkers for clinical severity. In this population not transfused for ≥90 days before sampling, the diagnostic sensitivity of the PK enzyme assay was 90% [95% confidence interval (CI) 77-97%], whereas the PK:HK ratio sensitivity was 98% (95% CI 87-100%). There was no correlation between PK enzyme activity and clinical severity. Transfusion requirements correlated with normalised erythrocyte ATP levels (r = 0·527, P = 0·0016) and PK-R protein levels (r = -0·527, P = 0·0028). PK-R protein levels were significantly higher in the never transfused [median (range) 40·1 (9·8-73·9)%] versus ever transfused [median (range) 7·7 (0·4-15·1)%] patients (P = 0·0014). The PK:HK ratio had excellent sensitivity for PK diagnosis, superior to PKLR exon sequencing. Given that the number of PKLR variants and genotype combinations limits prognostication based on molecular findings, PK-R protein level may be a useful prognostic biomarker of disease severity and merits further study.
丙酮酸激酶缺乏症(PKD)是最常见的遗传性非球形细胞溶血性贫血的病因,但在常规实践中其诊断仍然具有挑战性,并且尚未确定用于临床严重程度的生物标志物。本前瞻性研究纳入了来自北美 9 个中心的 41 例经分子证实的 PKD 患者,旨在评估丙酮酸激酶(PK)酶活性和 PK:己糖激酶(HK)酶活性比值的诊断敏感性,并评估红细胞 PK(PK-R)蛋白水平和红细胞代谢物作为临床严重程度的生物标志物。在本研究人群中,在采样前≥90 天未输血的情况下,PK 酶测定的诊断敏感性为 90%(95%CI77-97%),而 PK:HK 比值的敏感性为 98%(95%CI87-100%)。PK 酶活性与临床严重程度之间无相关性。输血需求与正常化红细胞 ATP 水平(r=0.527,P=0.0016)和 PK-R 蛋白水平(r=-0.527,P=0.0028)相关。从未输血(中位数(范围)40.1(9.8-73.9)%)与曾经输血(中位数(范围)7.7(0.4-15.1)%)的患者相比,PK-R 蛋白水平显著更高(P=0.0014)。PK:HK 比值对 PK 诊断具有出色的敏感性,优于 PKLR 外显子测序。鉴于 PKLR 变体和基因型组合的数量限制了基于分子发现的预后判断,PK-R 蛋白水平可能是疾病严重程度的有用预后生物标志物,值得进一步研究。